Descripción de la empresa
OnKure Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise dedicated to the discovery and development of precision medicines designed to target biologically validated drivers of cancers and other diseases. The company functions within the broader Healthcare sector, specifically positioning itself in the specialized Biotechnology industry where innovation often precedes commercial revenue generation. Its current market capitalization stands at $54.56M, supported by a workforce of 45 employees, while annual revenue data for the trailing twelve months is not available in the provided financial records. These valuation metrics indicate that the firm is a small-cap entity with a modest employee base, suggesting a high-risk, high-reward profile typical of early-stage biotechnology firms that have not yet achieved significant commercial scale or profitability.
Salud financiera
For the trailing twelve months, the company reported net income of $-59,517,000 and EBITDA of $-62,503,000, with revenue figures listed as not available. The substantial gap between the reported net income and the negative EBITDA reveals a cost structure heavily influenced by non-operating expenses or specific accounting adjustments common in clinical-stage development, where R&D spending often outpaces any current sales generation. Free cash flow stands at $-31,100,750, indicating that the company is consuming cash to fund its operations and development pipeline, which implies limited financial flexibility until external capital is raised or revenue milestones are met. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that reflects the absence of commercial sales or the immaturity of the revenue model where no profit has been realized to date. The balance sheet shows a cash position of $59.05M against total debt of $549,000, resulting in a debt-to-equity ratio of 0.98, which suggests a balance sheet that is relatively conservative regarding leverage despite the negative earnings. The current ratio is an exceptionally high 10.28, indicating robust short-term liquidity relative to current liabilities, a status often found in cash-rich, loss-making biotech companies. Return on Equity is -74.4% and Return on Assets is -44.5%, metrics that reveal management effectiveness is currently measured by asset utilization for growth rather than immediate profit generation, highlighting the capital-intensive nature of the business model.
Evaluación de valoración
The trailing P/E ratio is not available due to lack of earnings, while the forward P/E is listed at -1.40, implying that the market prices the stock based on anticipated future earnings that are currently negative. The price-to-book ratio is 0.97, indicating that the market values the company slightly below its tangible book value, which can suggest undervaluation or a lack of intangible asset recognition in the balance sheet. The price-to-sales ratio is not available, and the EV/EBITDA stands at 0.06, suggesting a valuation multiple that is heavily discounted given the company's negative earnings and lack of sales. The 52-week high is $5.10 and the 52-week low is $1.70; without a specific current price provided in the facts, the trading range indicates significant volatility within a span of $3.40 over the past year. The beta value is not available, which prevents a direct comparison of price volatility relative to the broader market, but the wide range between the high and low suggests inherent instability common in small-cap biotechnology equities.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue at this stage of development. Since the company does not pay dividends, the dividend yield is not available and the payout ratio is 0.0%, meaning the firm reinvests all available cash flow into research, development, and operational expansion rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current profitability and dividend income, relying entirely on external financing to sustain operations while pursuing clinical milestones for its lead product candidate, OKI-219.